Selected research
Market Structure
Global Nicotinamide Phosphoribosyltransferase Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Nicotinamide Phosphoribosyltransferase market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Nicotinamide Phosphoribosyltransferase is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Nicotinamide Phosphoribosyltransferase is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Nicotinamide Phosphoribosyltransferase is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Nicotinamide Phosphoribosyltransferase is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Nicotinamide Phosphoribosyltransferase include OncoTartis, Inc., Karyopharm Therapeutics, Inc., Genentech, Inc., FORMA Therapeutics, Inc., Calico LLC, Aurigene Discovery Technologies Limited and Angelini Group, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Nicotinamide Phosphoribosyltransferase market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Nicotinamide Phosphoribosyltransferase and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Nicotinamide Phosphoribosyltransferase sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Nicotinamide Phosphoribosyltransferase market size, projected growth trends, production technologies, key applications, and end-use industries.
Nicotinamide Phosphoribosyltransferase Segment by Company
OncoTartis, Inc.
Karyopharm Therapeutics, Inc.
Genentech, Inc.
FORMA Therapeutics, Inc.
Calico LLC
Aurigene Discovery Technologies Limited
Angelini Group
Nicotinamide Phosphoribosyltransferase Segment by Type
Lipids
Small Molecule Compounds
Hormone
Others
Nicotinamide Phosphoribosyltransferase Segment by Application
Breast Cancer
Parkinson's Disease
Acute Lung Injury
Others
Nicotinamide Phosphoribosyltransferase Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nicotinamide Phosphoribosyltransferase market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nicotinamide Phosphoribosyltransferase and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nicotinamide Phosphoribosyltransferase.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Nicotinamide Phosphoribosyltransferase market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Nicotinamide Phosphoribosyltransferase manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Nicotinamide Phosphoribosyltransferase in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Nicotinamide Phosphoribosyltransferase in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Lipids
- Small Molecule Compounds
- Hormone
- Others
Applications
- Breast Cancer
- Parkinson's Disease
- Acute Lung Injury
- Others
Companies covered
- OncoTartis, Inc.
- Karyopharm Therapeutics, Inc.
- Genentech, Inc.
- FORMA Therapeutics, Inc.
- Calico LLC
- Aurigene Discovery Technologies Limited
- Angelini Group
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Nicotinamide Phosphoribosyltransferase Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Nicotinamide Phosphoribosyltransferase Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Nicotinamide Phosphoribosyltransferase Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Nicotinamide Phosphoribosyltransferase Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Nicotinamide Phosphoribosyltransferase Market Dynamics
- 2.1 Nicotinamide Phosphoribosyltransferase Industry Trends
- 2.2 Nicotinamide Phosphoribosyltransferase Industry Drivers
- 2.3 Nicotinamide Phosphoribosyltransferase Industry Opportunities and Challenges
- 2.4 Nicotinamide Phosphoribosyltransferase Industry Restraints
3 Nicotinamide Phosphoribosyltransferase Market by Manufacturers
- 3.1 Global Nicotinamide Phosphoribosyltransferase Revenue by Manufacturers (2021-2026)
- 3.2 Global Nicotinamide Phosphoribosyltransferase Sales by Manufacturers (2021-2026)
- 3.3 Global Nicotinamide Phosphoribosyltransferase Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Nicotinamide Phosphoribosyltransferase Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Nicotinamide Phosphoribosyltransferase Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Nicotinamide Phosphoribosyltransferase Manufacturers, Product Type & Application
- 3.7 Global Nicotinamide Phosphoribosyltransferase Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Nicotinamide Phosphoribosyltransferase Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Nicotinamide Phosphoribosyltransferase Players Market Share by Revenue in 2025
- 3.8.3 2025 Nicotinamide Phosphoribosyltransferase Tier 1, Tier 2, and Tier 3
4 Nicotinamide Phosphoribosyltransferase Market by Type
- 4.1 Nicotinamide Phosphoribosyltransferase Type Introduction
- 4.1.1 Lipids
- 4.1.2 Small Molecule Compounds
- 4.1.3 Hormone
- 4.1.4 Others
- 4.2 Global Nicotinamide Phosphoribosyltransferase Sales by Type
- 4.2.1 Global Nicotinamide Phosphoribosyltransferase Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Nicotinamide Phosphoribosyltransferase Sales by Type (2021-2032)
- 4.2.3 Global Nicotinamide Phosphoribosyltransferase Sales Market Share by Type (2021-2032)
- 4.3 Global Nicotinamide Phosphoribosyltransferase Revenue by Type
- 4.3.1 Global Nicotinamide Phosphoribosyltransferase Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Nicotinamide Phosphoribosyltransferase Revenue by Type (2021-2032)
- 4.3.3 Global Nicotinamide Phosphoribosyltransferase Revenue Market Share by Type (2021-2032)
5 Nicotinamide Phosphoribosyltransferase Market by Application
- 5.1 Nicotinamide Phosphoribosyltransferase Application Introduction
- 5.1.1 Breast Cancer
- 5.1.2 Parkinson's Disease
- 5.1.3 Acute Lung Injury
- 5.1.4 Others
- 5.2 Global Nicotinamide Phosphoribosyltransferase Sales by Application
- 5.2.1 Global Nicotinamide Phosphoribosyltransferase Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Nicotinamide Phosphoribosyltransferase Sales by Application (2021-2032)
- 5.2.3 Global Nicotinamide Phosphoribosyltransferase Sales Market Share by Application (2021-2032)
- 5.3 Global Nicotinamide Phosphoribosyltransferase Revenue by Application
- 5.3.1 Global Nicotinamide Phosphoribosyltransferase Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Nicotinamide Phosphoribosyltransferase Revenue by Application (2021-2032)
- 5.3.3 Global Nicotinamide Phosphoribosyltransferase Revenue Market Share by Application (2021-2032)
6 Global Nicotinamide Phosphoribosyltransferase Sales by Region
- 6.1 Global Nicotinamide Phosphoribosyltransferase Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Nicotinamide Phosphoribosyltransferase Sales by Region (2021-2032)
- 6.2.1 Global Nicotinamide Phosphoribosyltransferase Sales by Region (2021-2026)
- 6.2.2 Global Nicotinamide Phosphoribosyltransferase Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Nicotinamide Phosphoribosyltransferase Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Nicotinamide Phosphoribosyltransferase Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Nicotinamide Phosphoribosyltransferase Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Nicotinamide Phosphoribosyltransferase Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Nicotinamide Phosphoribosyltransferase Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Nicotinamide Phosphoribosyltransferase Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Nicotinamide Phosphoribosyltransferase Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Nicotinamide Phosphoribosyltransferase Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Nicotinamide Phosphoribosyltransferase Revenue by Region
- 7.1 Global Nicotinamide Phosphoribosyltransferase Revenue by Region
- 7.1.1 Global Nicotinamide Phosphoribosyltransferase Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Nicotinamide Phosphoribosyltransferase Revenue by Region (2021-2026)
- 7.1.3 Global Nicotinamide Phosphoribosyltransferase Revenue by Region (2027-2032)
- 7.1.4 Global Nicotinamide Phosphoribosyltransferase Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Nicotinamide Phosphoribosyltransferase Revenue (2021-2032)
- 7.2.2 North America Nicotinamide Phosphoribosyltransferase Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Nicotinamide Phosphoribosyltransferase Revenue (2021-2032)
- 7.3.2 Europe Nicotinamide Phosphoribosyltransferase Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Nicotinamide Phosphoribosyltransferase Revenue (2021-2032)
- 7.4.2 Asia-Pacific Nicotinamide Phosphoribosyltransferase Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Nicotinamide Phosphoribosyltransferase Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Nicotinamide Phosphoribosyltransferase Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 OncoTartis, Inc.
- 8.1.1 OncoTartis, Inc. Company Information
- 8.1.2 OncoTartis, Inc. Business Overview
- 8.1.3 OncoTartis, Inc. Nicotinamide Phosphoribosyltransferase Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 OncoTartis, Inc. Nicotinamide Phosphoribosyltransferase Product Portfolio
- 8.1.5 OncoTartis, Inc. Recent Developments
- 8.2 Karyopharm Therapeutics, Inc.
- 8.2.1 Karyopharm Therapeutics, Inc. Company Information
- 8.2.2 Karyopharm Therapeutics, Inc. Business Overview
- 8.2.3 Karyopharm Therapeutics, Inc. Nicotinamide Phosphoribosyltransferase Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Karyopharm Therapeutics, Inc. Nicotinamide Phosphoribosyltransferase Product Portfolio
- 8.2.5 Karyopharm Therapeutics, Inc. Recent Developments
- 8.3 Genentech, Inc.
- 8.3.1 Genentech, Inc. Company Information
- 8.3.2 Genentech, Inc. Business Overview
- 8.3.3 Genentech, Inc. Nicotinamide Phosphoribosyltransferase Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Genentech, Inc. Nicotinamide Phosphoribosyltransferase Product Portfolio
- 8.3.5 Genentech, Inc. Recent Developments
- 8.4 FORMA Therapeutics, Inc.
- 8.4.1 FORMA Therapeutics, Inc. Company Information
- 8.4.2 FORMA Therapeutics, Inc. Business Overview
- 8.4.3 FORMA Therapeutics, Inc. Nicotinamide Phosphoribosyltransferase Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 FORMA Therapeutics, Inc. Nicotinamide Phosphoribosyltransferase Product Portfolio
- 8.4.5 FORMA Therapeutics, Inc. Recent Developments
- 8.5 Calico LLC
- 8.5.1 Calico LLC Company Information
- 8.5.2 Calico LLC Business Overview
- 8.5.3 Calico LLC Nicotinamide Phosphoribosyltransferase Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Calico LLC Nicotinamide Phosphoribosyltransferase Product Portfolio
- 8.5.5 Calico LLC Recent Developments
- 8.6 Aurigene Discovery Technologies Limited
- 8.6.1 Aurigene Discovery Technologies Limited Company Information
- 8.6.2 Aurigene Discovery Technologies Limited Business Overview
- 8.6.3 Aurigene Discovery Technologies Limited Nicotinamide Phosphoribosyltransferase Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Aurigene Discovery Technologies Limited Nicotinamide Phosphoribosyltransferase Product Portfolio
- 8.6.5 Aurigene Discovery Technologies Limited Recent Developments
- 8.7 Angelini Group
- 8.7.1 Angelini Group Company Information
- 8.7.2 Angelini Group Business Overview
- 8.7.3 Angelini Group Nicotinamide Phosphoribosyltransferase Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Angelini Group Nicotinamide Phosphoribosyltransferase Product Portfolio
- 8.7.5 Angelini Group Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Nicotinamide Phosphoribosyltransferase Value Chain Analysis
- 9.1.1 Nicotinamide Phosphoribosyltransferase Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Nicotinamide Phosphoribosyltransferase Production Mode & Process
- 9.2 Nicotinamide Phosphoribosyltransferase Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Nicotinamide Phosphoribosyltransferase Distributors
- 9.2.3 Nicotinamide Phosphoribosyltransferase Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst